Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized radioiodine therapy for metastatic differentiated thyroid carcinoma using 124I PET dosimetry
2020-002548-21Phase 2Active
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Oct 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iodine-131 in well-differentiated thyroid cancer (WDTC) and poorly differentiated thyroid carcinoma (PDTC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Complete response rate in soft tissue metastases. Started Oct 2020; status: active.
02
Drugs
iodine-131
03
Conditions
well-differentiated thyroid cancer (WDTC)poorly differentiated thyroid carcinoma (PDTC)
Beyond the preview
Go deeper on 2020-002548-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002548-21.